Naphazoline

RESPIRATORY SYSTEM

Key facts

Naphazoline is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1971. DrugCentral lists 9 molecular targets, including ADRA1A, Adra2b|Adra2c|Adra2a and Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a. Recorded indications include Ocular Itching and Red eye.

• Approval status: ofp (first approved 1971 by the FDA).
• Molecular targets: ADRA1A, Adra2b|Adra2c|Adra2a, Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a and Adra1b|Adra1d|Adra1a (9 listed in DrugCentral).
• Indications: Ocular Itching and Red eye.
• ATC code: R01AA08 (Sympathomimetics, plain).
• Molecular formula: C14H14N2; molecular weight 210.28 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Ocular Itching
• Red eye

Contraindications (8)

• Angle-closure glaucoma
• Diabetes mellitus
• Disorder of cardiovascular system
• Eye infection
• Hyperglycemia
• Hypertensive disorder
• Hyperthyroidism
• Injury of eye region

Mechanism & targets

Molecular targets (9)

Target	Gene	Action	Activity
Alpha-1A adrenergic receptor	ADRA1A	agonist	EC50 8.90
Adrenergic receptor alpha-2	Adra2b|Adra2c|Adra2a	unknown	Ki 8.24
Adrenergic receptor alpha	Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a	unknown	Ki 8.24
Adrenergic receptor alpha-1	Adra1b|Adra1d|Adra1a	unknown	EC50 7.92
Alpha-2A adrenergic receptor	ADRA2A	agonist	Ki 7.68
Nischarin	NISCH	unknown	Ki 6.92
Nischarin	Nisch	unknown	Ki 6.61
Alpha-2B adrenergic receptor	ADRA2B	agonist	Ki 6.39
Alpha-2C adrenergic receptor	ADRA2C	agonist	Ki 6.39

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1971-06-07	FDA	—	NOVARTIS

ATC classification

ATC code	Therapeutic hierarchy
R01AA08	RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Sympathomimetics, plain
R01AB02	RESPIRATORY SYSTEM › NASAL PREPARATIONS › DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE › Sympathomimetics, combinations excl. corticosteroids
S01GA01	SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Sympathomimetics used as decongestants
S01GA51	SENSORY ORGANS › OPHTHALMOLOGICALS › DECONGESTANTS AND ANTIALLERGICS › Sympathomimetics used as decongestants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Catarrh	298.3
Burns second degree	294.1
Steroid dependence	289.6
Hypopnoea	269.5
Alcohol poisoning	255.3
Parosmia	253.6
Gingival pain	250.2
Rhinitis	222.7
Cardiac murmur	213.3
Impaired work ability	195.5
Bronchiectasis	192.3
Nightmare	186.0

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Naphazoline is on its molecule page.

• Molecular formula: C₁₄H₁₄N₂
• Molecular weight: 210.28 g/mol
• CAS number: 835-31-4
• InChIKey: CNIIGCLFLJGOGP-UHFFFAOYSA-N
• PubChem CID: 4436

C(C1=NCCN1)C1=CC=CC2=CC=CC=C12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Naphazoline used for?

DrugCentral lists the following indications for Naphazoline: Ocular Itching and Red eye.

How does Naphazoline work?

Its molecular targets in DrugCentral include ADRA1A (agonist), Adra2b|Adra2c|Adra2a, Adra1b|Adra2b|Adra2c|Adra2a|Adra1d|Adra1a and Adra1b|Adra1d|Adra1a.

When was Naphazoline first approved?

Naphazoline was first approved by the FDA in 1971.

What is the chemical formula of Naphazoline?

Naphazoline has the molecular formula C14H14N2 and a molecular weight of 210.28 g/mol.

Sources

• DrugCentral drug card 3369 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1706 — compound record and bioactivity
• PubChem CID 4436 — chemical identifiers
• DrugBank DB06711 — drug record
• FDA UNII H231GF11BV — substance identity
• DailyMed: FDA labels for Naphazoline — current prescribing information (label search)
• UniProt P35348 (ADRA1A) — target protein
• UniProt P08913 (ADRA2A) — target protein
• UniProt Q9Y2I1 (NISCH) — target protein
• UniProt P18089 (ADRA2B) — target protein
• UniProt P18825 (ADRA2C) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.